AXIOS January 3, 2024
Tina Reed

The discontinuation of a popular asthma inhaler this week has raised alarms among doctors who worry about patients, particularly kids, experiencing delays in accessing alternatives.

Why it matters: The potential gaps in access come at a peak time in respiratory virus season, when breathing conditions like asthma, commonly treated with the inhalers, are more likely to be exacerbated.

  • The case of GlaxoSmithKline‘s discontinued inhaler also highlights health care’s unusual economics and the challenges in curbing costs.

Catch up quick: GSK told the Food and Drug Administration last year it would stop making inhaled steroid medications Flovent HFA and Flovent Diskus as of Jan. 1. Patients would instead have access to an “authorized generic” version of these products, which...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Patient / Consumer, Pharma, Pharma / Biotech, Primary care, Provider
Related Articles:
California Sets 15% Goal for Primary Care Spending by 2034
Lessons from Forward Health: How direct primary care is the future of health care
5 objectives for achieving high-quality primary care at the state level
Are telehealth visits for pediatric primary care associated with higher rates of health care utilization?
70% of Americans want primary care providers to address mental health

Share This Article